Radiofrequency Ablation News and Research RSS Feed - Radiofrequency Ablation News and Research

Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
Guidelines for management of small renal masses questioned

Guidelines for management of small renal masses questioned

Partial nephrectomy and percutaneous ablation for small and localised renal masses produce similar rates of local tumour recurrence, report US researchers. [More]
Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology. [More]
Celsion announces financial results for second quarter ended 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. [More]
Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical resection markedly improves survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the July issue of the Journal of the American College of Surgeons. [More]
First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

Gynesonics, Inc., a women's healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company's newly-designed VizAblate System. [More]
Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

According to a new systematic review article, radiofrequency ablation and complete endoscopic resection are equally effective in the short-term treatment of dysplastic Barrett's esophagus, but adverse event rates are higher with complete endoscopic resection. [More]
New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). [More]
Nurses guide patients into trance during procedure

Nurses guide patients into trance during procedure

Visualising a safe place reduces operative pain, according to research presented today at EuroHeartCare 2014. Nurses guided patients into a trance and found it helped patients cope with pain and anxiety during ablation of atrial fibrillation (AF). [More]
Doctors devise new way to treat atrial fibrillation

Doctors devise new way to treat atrial fibrillation

Doctors in the U.S. and Japan have devised a way to treat atrial fibrillation by adding a little alcohol to minimally invasive therapies that target a cluster of misbehaving nerves known to trigger arrhythmia. In the most recent Journal of the American College of Cardiology (online before print), the researchers say the new therapy may dull or stop the transmission of electrical impulses that cause atrial fibrillation. [More]
Sedation before nerve block significantly increases false-positive results, shows study

Sedation before nerve block significantly increases false-positive results, shows study

New research suggests that sedating patients before a nerve block needed to diagnose or treat chronic pain increases costs, risks and unnecessary surgeries, and sedation does nothing to increase patient satisfaction or long-term pain control. [More]
ASA's recommendations to help patients avoid unnecessary tests for chronic pain

ASA's recommendations to help patients avoid unnecessary tests for chronic pain

Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary. [More]
Research review examines effectiveness of treatments for chronic skin wounds

Research review examines effectiveness of treatments for chronic skin wounds

A systematic review of 66 research papers focused on the treatment of skin ulcers suggests that most are so technically flawed that their results are unreliable. And even of those that pass muster, there is only weak evidence that some treatments work better than standard compression therapy or special stockings. [More]

CardioFocus completes HeartLight EAS pivotal trial enrollment for symptomatic paroxysmal AF

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF. [More]
Radiofrequency ablation leads to remission of dysplastic Barrett's esophagus

Radiofrequency ablation leads to remission of dysplastic Barrett's esophagus

Radiofrequency ablation (RFA) leads to remission for 91 percent of patients with dysplastic Barrett's esophagus, according to new figures published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
EHRA, AEPC release joint consensus statement on treatment of paediatric arrhythmias

EHRA, AEPC release joint consensus statement on treatment of paediatric arrhythmias

A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association of the European Society of Cardiology and the Association for European Paediatric and Congenital Cardiology. [More]

European study to evaluate CardioFocus' HeartLight Endoscopic Ablation System in AF patients

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF. [More]
AtriCure's Bipolar RF Ablation System shows promising results in persistent Afib patients

AtriCure's Bipolar RF Ablation System shows promising results in persistent Afib patients

A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation during last week's International Society for Minimally Invasive Cardiothoracic Surgery meeting being held in Prague, Czech Republic. [More]
Renal denervation reduces blood pressure for patients not responding to drug therapy

Renal denervation reduces blood pressure for patients not responding to drug therapy

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy. [More]